Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C

Motoyuki Kohjima, Miho Kurokawa, Munechika Enjoji, Tsuyoshi Yoshimoto, Tsukasa Nakamura, Tomoko Ohashi, Kunitaka Fukuizumi, Naohiko Harada, Yusuke Murata, Kazuhisa Matsunaga, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1% at days 3 and 7, appearing similar regardless of baseline renal function. Urinary β2-microglobulin levels were elevated and were significantly higher in patients with renal dysfunction, as compared with those not exhibiting renal dysfunction (P<0.05). The reduction in renal function was milder in patients treated with a reduced TVR dose, and these patients had a significantly lower risk of developing renal dysfunction (P<0.05). Using a multivariate analysis, TVR dose and eGFR at the initiation of treatment were identified as significant contributory factors in the development of renal dysfunction. Reduction in TVR dose did not lead to a significant increase in the viral kinetics of HCV or detrimental effects on the sustained viral response (SVR) rate. It is hypothesized that renal dysfunction during TVR treatment is caused by damage of the renal tubule, in addition to pre-renal dysfunction, and that reduction in TVR dose reduces the rate of renal dysfunction without causing a significant decrease in the SVR rate.

Original languageEnglish
Pages (from-to)1781-1787
Number of pages7
JournalExperimental and Therapeutic Medicine
Volume11
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Chronic Hepatitis C
Kidney
Therapeutics
Glomerular Filtration Rate
Hepacivirus
telaprevir
Ribavirin
Interferons
Creatinine
Multivariate Analysis
Sodium
Genotype

All Science Journal Classification (ASJC) codes

  • Immunology and Microbiology (miscellaneous)
  • Cancer Research

Cite this

Kohjima, M., Kurokawa, M., Enjoji, M., Yoshimoto, T., Nakamura, T., Ohashi, T., ... Nakamuta, M. (2016). Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C. Experimental and Therapeutic Medicine, 11(5), 1781-1787. https://doi.org/10.3892/etm.2016.3133

Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C. / Kohjima, Motoyuki; Kurokawa, Miho; Enjoji, Munechika; Yoshimoto, Tsuyoshi; Nakamura, Tsukasa; Ohashi, Tomoko; Fukuizumi, Kunitaka; Harada, Naohiko; Murata, Yusuke; Matsunaga, Kazuhisa; Kato, Masaki; Kotoh, Kazuhiro; Nakamuta, Makoto.

In: Experimental and Therapeutic Medicine, Vol. 11, No. 5, 01.05.2016, p. 1781-1787.

Research output: Contribution to journalArticle

Kohjima, M, Kurokawa, M, Enjoji, M, Yoshimoto, T, Nakamura, T, Ohashi, T, Fukuizumi, K, Harada, N, Murata, Y, Matsunaga, K, Kato, M, Kotoh, K & Nakamuta, M 2016, 'Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C', Experimental and Therapeutic Medicine, vol. 11, no. 5, pp. 1781-1787. https://doi.org/10.3892/etm.2016.3133
Kohjima, Motoyuki ; Kurokawa, Miho ; Enjoji, Munechika ; Yoshimoto, Tsuyoshi ; Nakamura, Tsukasa ; Ohashi, Tomoko ; Fukuizumi, Kunitaka ; Harada, Naohiko ; Murata, Yusuke ; Matsunaga, Kazuhisa ; Kato, Masaki ; Kotoh, Kazuhiro ; Nakamuta, Makoto. / Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C. In: Experimental and Therapeutic Medicine. 2016 ; Vol. 11, No. 5. pp. 1781-1787.
@article{6800ab1cd6b14d77b916ed8d0200c1d9,
title = "Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C",
abstract = "Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1{\%} at days 3 and 7, appearing similar regardless of baseline renal function. Urinary β2-microglobulin levels were elevated and were significantly higher in patients with renal dysfunction, as compared with those not exhibiting renal dysfunction (P<0.05). The reduction in renal function was milder in patients treated with a reduced TVR dose, and these patients had a significantly lower risk of developing renal dysfunction (P<0.05). Using a multivariate analysis, TVR dose and eGFR at the initiation of treatment were identified as significant contributory factors in the development of renal dysfunction. Reduction in TVR dose did not lead to a significant increase in the viral kinetics of HCV or detrimental effects on the sustained viral response (SVR) rate. It is hypothesized that renal dysfunction during TVR treatment is caused by damage of the renal tubule, in addition to pre-renal dysfunction, and that reduction in TVR dose reduces the rate of renal dysfunction without causing a significant decrease in the SVR rate.",
author = "Motoyuki Kohjima and Miho Kurokawa and Munechika Enjoji and Tsuyoshi Yoshimoto and Tsukasa Nakamura and Tomoko Ohashi and Kunitaka Fukuizumi and Naohiko Harada and Yusuke Murata and Kazuhisa Matsunaga and Masaki Kato and Kazuhiro Kotoh and Makoto Nakamuta",
year = "2016",
month = "5",
day = "1",
doi = "10.3892/etm.2016.3133",
language = "English",
volume = "11",
pages = "1781--1787",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C

AU - Kohjima, Motoyuki

AU - Kurokawa, Miho

AU - Enjoji, Munechika

AU - Yoshimoto, Tsuyoshi

AU - Nakamura, Tsukasa

AU - Ohashi, Tomoko

AU - Fukuizumi, Kunitaka

AU - Harada, Naohiko

AU - Murata, Yusuke

AU - Matsunaga, Kazuhisa

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Nakamuta, Makoto

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1% at days 3 and 7, appearing similar regardless of baseline renal function. Urinary β2-microglobulin levels were elevated and were significantly higher in patients with renal dysfunction, as compared with those not exhibiting renal dysfunction (P<0.05). The reduction in renal function was milder in patients treated with a reduced TVR dose, and these patients had a significantly lower risk of developing renal dysfunction (P<0.05). Using a multivariate analysis, TVR dose and eGFR at the initiation of treatment were identified as significant contributory factors in the development of renal dysfunction. Reduction in TVR dose did not lead to a significant increase in the viral kinetics of HCV or detrimental effects on the sustained viral response (SVR) rate. It is hypothesized that renal dysfunction during TVR treatment is caused by damage of the renal tubule, in addition to pre-renal dysfunction, and that reduction in TVR dose reduces the rate of renal dysfunction without causing a significant decrease in the SVR rate.

AB - Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1% at days 3 and 7, appearing similar regardless of baseline renal function. Urinary β2-microglobulin levels were elevated and were significantly higher in patients with renal dysfunction, as compared with those not exhibiting renal dysfunction (P<0.05). The reduction in renal function was milder in patients treated with a reduced TVR dose, and these patients had a significantly lower risk of developing renal dysfunction (P<0.05). Using a multivariate analysis, TVR dose and eGFR at the initiation of treatment were identified as significant contributory factors in the development of renal dysfunction. Reduction in TVR dose did not lead to a significant increase in the viral kinetics of HCV or detrimental effects on the sustained viral response (SVR) rate. It is hypothesized that renal dysfunction during TVR treatment is caused by damage of the renal tubule, in addition to pre-renal dysfunction, and that reduction in TVR dose reduces the rate of renal dysfunction without causing a significant decrease in the SVR rate.

UR - http://www.scopus.com/inward/record.url?scp=84961782256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961782256&partnerID=8YFLogxK

U2 - 10.3892/etm.2016.3133

DO - 10.3892/etm.2016.3133

M3 - Article

AN - SCOPUS:84961782256

VL - 11

SP - 1781

EP - 1787

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 5

ER -